Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?

Stacy Loeb, Angela Gupta, Lia Losonczy, Jeffrey Tosoian, Patrick C. Walsh

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: To determine whether alpha-blockers, commonly used for the treatment of benign prostatic hyperplasia, are associated with prostate cancer risk. RECENT FINDINGS: Alpha-blockers have been associated with a reduced risk of prostate cancer aggressiveness in some observational studies and an increased risk in other studies. However, this relationship is complex as different alpha-blockers have divergent effects in laboratory studies and there are many confounders in daily practice such as differential screening practices. SUMMARY: Both benign prostatic hyperplasia and prostate cancer are common conditions in the aging male population, such that an interaction between alpha-blockers and prostate cancer risk is clinically relevant. Prospective evidence is necessary to establish a definitive link.

Original languageEnglish (US)
Pages (from-to)2-4
Number of pages3
JournalCurrent opinion in urology
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2013

Keywords

  • BPH
  • alpha-blockers
  • prognosis
  • prostate cancer
  • risk

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?'. Together they form a unique fingerprint.

  • Cite this